Farallon Capital Opposes Terms of Merck’s Acceleron Takeover
This article is for subscribers only.
Another top-10 holder in Acceleron Pharma Inc. has come out against its proposed $11.5 billion takeover by Merck & Co. Inc., arguing the sale price undervalues the company.
Farallon Capital Management, which owns a more than 4% stake in Acceleron, said in an emailed statement that it appreciated the value the management team has created and the strategic position it has achieved. But it said it doesn’t support the terms of the sale.